CBIS: February 28, 2012 (FinancialWire) -- Pharmaceutical cannabis products company Cannabis Science Inc. (OTCBB: CBIS) announced Dr. Moe Afaneh has identified the company's first four Cannabis Science brand products and that Afaneh expects to have a full report this week with the new product offering launch plan including nationwide manufacturing and distribution.
The Cannabis Science executive team is reportedly finalizing negotiations for the manufacturing and national distribution or this new product line, with the commercialization process well underway, including securing manufacturing partners that have the resources to support national distribution and retail outlets such as pharmacies through to grocery outlets and other multi-national retail outlets, according to Cannabis Science.
The company said the new product launch is the first mandate for its newly-appointed COO, Dr. Afaneh, who the company sais is is now ahead of schedule for the launch.
Cannabis Science president Dr. Robert Melamede commented, "Dr. Moe is ahead of our projections and we are very proud. The retail availability of these products should increase revenue and that's great for Cannabis Science and our shareholders. I am confident that we will realize our financial plans and goals that should bring Cannabis Science to profitability in 2014. I look forward to using many of these products for myself and my family in the near future."
Cannabis Science Inc. (approx. market cap US$ 38.0 mil.), a development stage company, engages in the development, production and commercialization of phytocannabinoid-based pharmaceutical products. It primarily focuses on developing medications to treat autism, blood pressure, cancer, cancer side effects, HIV and other illnesses, including general health maintenance. The company is based in Denver, Colorado
